Corrigendum to “Insulin-like growth Factors I and II receptors in the breast cancer disparity” among African-American women [Growth Hormone & IGF Research 20 (2010) 245–254] ((****) ** (***–***), (S1096637410000249), (10.1016/j.ghir.2010.03.001));Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women

Growth Hormone and IGF Research

Volumn 20, Issue 3, 2010, Pages 245-254

  Kalla Singh, S ^a   Tan, Q W ^a   Brito, C ^a   De Leon M ^a   De Leon D ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Health disparities; IGF II; IGF IR; IGF2R

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; PROTEIN SHC; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CAUCASIAN; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; GENE EXPRESSION; HEALTH DISPARITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; WESTERN BLOTTING;

EID: 77953082733     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2022.101512     Document Type: Erratum

References (50)

1. Surveillance, epidemiology, and end results program (SEER) SEER stat database: mortality-all COD, public-use with state, total U.S. for expanded races/Hispanics (1991-2001). National Cancer Institute, DC-CPS, Surveillance Research Program, Cancer Statistics Branch, Released April 2004. http://www.seer.cancer.gov.
2. De Myets P. The structural basis of insulin and insulin-like growth factor-1 receptor binding and negative cooperativity, and its relevance to mitogenic versus metabolic signaling. Diabetologia 1994, 37(Suppl 2):S135-S148.
3. Morrione A., Valentinis B., Xu S.Q., Yumet G., Louvi A., Efstratiadis A., Baserga R. IGF-II stimulates cell proliferation through the insulin receptor. Proc. Natl Acad. Sci. USA 1997, 94:3777-3782.
4. Sciacca L., Constantino A., Pandini G., Mineo R., Frasca F., Scalia P., Sbraccia P., Goldfine I.D., Vigneri R., Belfiore A. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999, 18:2471-2479.
5. Voskuil D., Bosma A., Vrieling A., Rookus M., Veer L. IGF system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res. Treat. 2004, 84:225-233.
6. Pacher M., Seewald M., Mikula M., Oehler S., Mogg M., Vinatzer U., Eger A., Schweifer N., Varecka R., Sommergruber W., Mikulits W., Schreiber M. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis 2007, 49-59.
7. S. Kalla Singh, Q.W. Tan, M. De León, D. De León, Differential IGF-II expression: a potential role for breast cancer survival disparity, Growth Horm. IGF Res. (2010) Jan 19 PMID: 20089431.
8. Pinheiro S.P., Holmes M.D., Pollak M.N., Barbieri R.L., Hankinson S.E. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2147-2153.
9. Werner H., Woloschak M., Adamo M., Shen-Orr Z., Roberts C.T., LeRoith D. Developmental regulation of the rat IGF1 receptor gene. Proc. Natl Acad. Sci. USA 1989, 86:7451-7455.
10. Beitner-Johnson D., Werner H., Roberts C.T., LeRoith D. Regulation of IGF1R gene expression by Sp1: physical and functional interactions of Sp1 at GC boxes and at a CT element. Mol. Endocrinol. 1995, 9:1147-1156.
11. Condorelli G., Buenos R., Smith R.J. Two alternative spliced forms of the human IGF1R have distinct biological activities and internalization kinetics. J. Biol. Chem. 1994, 269:8510-8516.
12. Sarfstein R., Maor S., Reisner N., Abramovitch S., Werner H. Transcriptional regulation of the IGF-1 receptor gene in breast cancer. Mol. Cell. Endocrinol. 2006, 252:241-246.
13. Sell C., Ubini M., Rubin R., Liu J.P., Efstratiadis A., Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblast lacking type 1 insulin-like growth factor receptor. Proc. Natl Acad. Sci. USA 1993, 90:11217-11221.
14. Schnarr B., Strunz K., Ohsam J., Benner A., Wacker J., Mayer D. Down-regulation of IGF1R and IRs-1 expression in advanced human breast cancer. Int. J. Cancer 2000, 89:506-513.
15. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. IGF1R signaling and resistance to trastuzumab (Herceptin). J. Natl Cancer Inst. 2001, 93:1852-1857.
16. Roberts C.T. Control of IGF action by regulation of IGF1R expression. Endocr. J. 1996, 43:S49-S55.
17. Hawkes C., Amritraj A., MacDonald R.G. Heterotrimeric G proteins and the single-transmembrane domain IGF-II/M6P receptor: Functional interaction and relevance to cell signaling. Mol. Neurobiol. 2007, 35:329-345.
18. De Leon D.D., Terry C., Asmerom Y., Nissley P. IGF-II modulates the routing of Cathepsin D in MCF-7 breast cancer cells. Endocrinology 1996, 137:1851-1859.
19. Faridi J.S., Mohan S., De Léon D. Modulation of Cathepsin D routing by IGF-II involves IGF-II binding to IGF-II/M6P receptor in MCF-7 breast cancer cells. Growth Factors 2004, 22:169-177.
20. Capony F., Rougeot C., Montcourrier P., Cavailles V., Salazar G., Rochefort H. Increased secretion, altered processing and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res. 1989, 49:3904-3909.
21. Rochefort H., Cavailles V., Augereau P., CApony F., Maudelonde T., Touitou I., et al. Overexpression and hormonal regulation of procathepsin D in mammary and endometrial cancer. J. Steroid Biochem. 1989, 34:177-182.
22. Funk B., Kessler U., Eisenmenger W., Hansmann A., Kolb H.J., Kiess W. Expression of the IGF-II/M6P receptor in multiple human tissues during fetal life and early infancy. J. Clin. Endocrinol. Metab. 1992, 75:424-431.
23. Hankins G.R., De Souza A.T., Bentley R.C., et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996, 12:2003-2009.
24. Piao Z., Choi Y., Park C., Lee W.J., Park J.H., Kim H. Deletion of the M6P/IGF2R gene in primary hepatocellular carcinoma. Cancer Lett. 1997, 120:39-43.
25. Yamada T., De Souza A.T., Finkelstein S., Jirtle R.L. Loss of the gene encoding M6P/IGF2R is an early event in liver carcinogenesis. Proc. Natl Acad. Sci. USA 1997, 94:10351-10355.
26. Ikezu T., Okamoto T., Giambarella U., Yokota T., Nishimoto I. In vivo coupling of IGF-II/M6P receptor to heteromeric G proteins. J. Biol. Chem. 1995, 270:29224-29228.
27. Albain K.S., Unger J.M., Crowley J.J., Coltman C.A., Hershman D.L. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology group. J. Natl Cancer Inst. 2009, 101:984-992.
28. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C., Nielsen T.O., Moorman P.G., Earp H.S., Millikan R.C. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295:2492-2502.
29. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of ER (-), PR (-), and HER2 (-) invasive breast cancer, the so called triple negative phenotype: a population-based study from the California cancer registry. Cancer 2007, 109:1721-1728.
30. Polite B.N., Cirrincione C., Fleming G.F., Berry D.A., Seidman A., Muss H., Norton L., Shapiro C., Bakri K., Marcom K., Lake D., Schwartz J.H., Hudis C., Winer E.P. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840 - cancer and leukemia group B. J. Clin. Oncol. 2008, 26:2659-2665.
31. Tennant M.K., Thrasher J.B., Twomey P.A., Drivdahl R.H., Birnbaum R.S., Plymate S.R. Protein and mRNA for the IGF1R is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to the benign prostate epithelium. J. Clin. Endocrinol. Metab. 1996, 81:3774-3782.
32. Shin A., Ren Z., Shu X.-O., Cai Q., Gao Y.-T., Zheng W. Expression patterns of IGF-1 and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res. Treat. 2007, 105:55-61.
33. Carboni J.M., Lee A.V., Hadsell D.L., Rowley B.R., Lee F.Y., Bol D.K., Camuso A.E., Gottardis M., Greer A.F., Ho C.P., Hurlburt W., Li A., Saulnier M., Velaparthi U., Wang C., Wen M.L., Westhouse R.A., Wittman M., Zimmermann K., Rupnow B.A., Wong T.W. Tumor development by transgenic expression of a constitutively active IGF1 receptor. Cancer Res. 2005, 65:3781-3787.
34. Jones R.A., Campbell C.I., Gunther E.J., Chodosh L.A., Petrik J.J., Khokha R., Moorehead R.A. Transgenic overexpression of IGF1R disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007, 26:1636-1644.
35. Olopade O.I., Fackenthal J.D., Dunston G., Tainsky M.A., Collins F., Whitfield-Broome C. Breast cancer genetics in African Americans. Cancer 2003, 97:236-245.
36. Pal T., Permuth-Wey J., Holtje T., Sutphen R. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1794-1799.
37. Joe A.K., Hibshoosh H. African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 2005, 104:661-662.
38. Newman L.A. Breast carcinoma in African-American and white women. Application of molecular biology to understand outcome disparities. Cancer 2004, 101:1261-1263.
39. Jones B.A., Kasl S.V., Howe C.L., Lachman L., Dubrow R., Curnen M.M., Soler-Vila H., Beeghly A., Duan F., Owens P. African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 2004, 101:1293-1301.
40. Maor S., Yosepovich A., Papa M.Z., Yarden R.I., Mayer D., Friedman E., Werner H. Elevated IGF1R levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett. 2007, 257:236-243.
41. Burroughs K.D., Howe S.R., Okubo Y., Fuchs-Young R., LeRoith D., Walker C.L. Dysregulation of IGF-1 signaling in uterine leiomyoma. J. Endocrinol. 2002, 172:83-93.
42. Knowlden J.M., Hutcheson I.R., Barrow D., Gee J.M., Nicholson R.I. IGF1R signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005, 146:4609-4618.
43. S. Kalla Singh, Q.W. Tan, C. Brito, M. De León, C. Garberoglio, D. De León, Differential IGF-II expression: a potential role for breast cancer survival disparity, Growth Horm. IGF Res. (2010) PMID: 20089431.
44. Chan B.T., Lee A.V. Insulin receptor substrate and breast tumorogenesis. J. Mamm. Gland Biol. Neoplasia 2008, 13:415-422.
45. Ravichandran K.S. Signaling via Shc family adapter proteins. Oncogene 2001, 20:6322-6330.
46. Delaine C., Alvino C.L., McNeil K.A., Mulhen T.D., Gauguin L., De Myets P., Jones E.Y., Brown J., Wallace J.C., Forbes B.E. A novel binding site for the human IGF-II/M6P receptor on IGF-II. J. Biol. Chem. 2007, 282(26):18886-18894.
47. Oka Y., Rozek L.M., Czech M.P. Direct demonstration of rapid IGF2R initialization and recycling in rat adipocytes. Insulin stimulates 125I-IGF-II degradation by modulating the IGF2R recycling process. J. Biol. Chem. 1985, 260:9435-9442.
48. Faust P.L., Chirgwin J.M., Kornfeld S. Renin, a secretory glycoprotein, acquires phosphomannosyl residues. J. Cell Biol. 1987, 105:1947-1955.
49. Lee S.-J., Nathans D. Proliferin secreted by cultured cells binds to mannose-6-phosphate receptors. J. Biol. Chem. 1988, 263:3521-3527.
50. Blanchard F., Duplomb L., Raher S., Vusio P., Hoflack B., Jacques Y., Godard A. M6P/IGF-II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitor factor. J. Biol. Chem. 1988, 273:20886-20893.